European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study

D. Capellà, J. R. Laporte, X. Vidal, B. E. Wiholm, B. Bégaud, M. J.S. Langman, M. Rawlins

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)

Abstract

Objective: Euronet, a case-population surveillance scheme, aims to estimate the risk of certain rare conditions which are commonly iatrogenic, by comparing drug use amongst non-selective cases with overall drug use in the general population. Methods: The method is based on three provisos: (1) all incident cases (irrespective of suspected aetiology) should be ascertained and studied; (2) a full drug history should be obtained from cases by direct interview; and (3) drug-use data for the products of interest should be available for this population from which cases are chosen. The feasibility of this problem-oriented approach for the identification of new signals of adverse drug reactions and for risk estimation will be tested in relation to agranulocytosis, Stevens-Johnson syndrome and toxic epidermal necrolysis in four defined areas in Europe, totalling 19 x 106 inhabitants, with these latest two outcomes being studied in only three regions. The design, methods and main limitations of this case-population surveillance approach are described.
Original languageEnglish
Pages (from-to)299-302
JournalEuropean Journal of Clinical Pharmacology
Volume53
DOIs
Publication statusPublished - 19 Feb 1998

Keywords

  • European network
  • Surveillance of rare disease

Fingerprint Dive into the research topics of 'European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study'. Together they form a unique fingerprint.

  • Cite this